Tier 4 — mechanistic
HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study
Clinical and molecular hepatology
2025
31(3):1071-1083
Bibliography
- PubMed
- PMID 40258699
- PubMed Central
- PMC12260645
- Trial registry
- View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
- Funding
- Indexed support: HighTide Therapeutics, Inc.. See the publication for grant details.
- Competing interests
- The HTD1801 development program includes HighTide-affiliated authors; see the complete individual disclosures.
Study snapshot
| Design | Companion clinical surrogate analysis with separate animal experiments |
|---|---|
| Model | Human participants; see population |
| Sample | 100 patients from an earlier phase II trial; separate hamster groups |
| Intervention | Secondary noninvasive-marker analysis of HTD1801; hamster histology experiments |
| Duration | 18-week human trial; 6-week animal experiment |
| Endpoints | Glycemic, lipid or liver measures; Dose response; Safety and tolerability |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
